Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017.

ABSTRACT:

Objective

To examine trends in the direct acting antiviral (DAA) uptake in a multi-state Medicaid population with hepatitis C virus (HCV) prior to and after ledipasvir/sofosbuvir (LDV/SOF) approval and changes in prior authorization (PA) requirements.

Data sources

Analyses utilized enrollment, medical, and pharmacy claims in four states, December 2013-December 2017.

Study design

An interrupted time series examined trends in uptake (1+ claim for a DAA) before and after two events: LDV/SOV approval (October 2014) and lifting of PA requirements for 40% of members (July 2016). Analyses were also performed in subgroups defined by the number and dates of change in PA requirements in members' Medicaid plans.

Data collection/extraction methods

Members aged 18-64 years

SUBMITTER: Clements KM 

PROVIDER: S-EPMC9643082 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature